-transparent.png){kind=logo}
An hplc method is described which determines debrisoquine and its metabolite, 4-hydroxydebrisoquine, quantitatively after conversion of the guanidine moieties into the corresponding pyrimidines. Sensitivity, precision, and accuracy have been sufficient enough for the reliable hydroxylation phenotyping of 145 non-related healthy volunteers (64 males, 81 females, 31-80 years). 17 (11%) were poor metabolizers of debrisoquine (gene frequency: 34.2%).
Related Publications
M Zschiesche, and
W Hanke, and
W Siegmund, and
G Franke, and
A Wilke
January 1992,
Psychopharmacology bulletin,
M Zschiesche, and
W Hanke, and
W Siegmund, and
G Franke, and
A Wilke
January 1988,
European journal of clinical pharmacology,
M Zschiesche, and
W Hanke, and
W Siegmund, and
G Franke, and
A Wilke
January 1989,
European journal of clinical pharmacology,
M Zschiesche, and
W Hanke, and
W Siegmund, and
G Franke, and
A Wilke
January 1991,
Therapie,
M Zschiesche, and
W Hanke, and
W Siegmund, and
G Franke, and
A Wilke
March 1991,
Acta neurologica Scandinavica,
M Zschiesche, and
W Hanke, and
W Siegmund, and
G Franke, and
A Wilke
March 1994,
Annals of the rheumatic diseases,
M Zschiesche, and
W Hanke, and
W Siegmund, and
G Franke, and
A Wilke
December 1988,
Pharmacological research communications,
M Zschiesche, and
W Hanke, and
W Siegmund, and
G Franke, and
A Wilke
September 1990,
Lancet (London, England),
M Zschiesche, and
W Hanke, and
W Siegmund, and
G Franke, and
A Wilke
October 1990,
Journal of the National Cancer Institute,
M Zschiesche, and
W Hanke, and
W Siegmund, and
G Franke, and
A Wilke
May 1986,
British journal of clinical pharmacology,
